www.ijarp.com ISSN 2456-9992 Page: 01-07

International Journal Advanced Research Publications

Review Article

Volume: 02
Issue: 04

PRECISION ONCOLOGY: A COMPREHENSIVE REVIEW OF VECTOR ENGINEERING, CRISPR ADVANCEMENTS, AND 2026 CLINICAL PERSPECTIVES IN CANCER GENE THERAPY

Nisar Ahmad Waza*[1], Madhukar Prabhash[2]

[1]Research Scholar, Department of Pharmacy, Faculty of Pharmaceutical Science, Mewar University, Gangrar, Chittorgarh-312901, Rajasthan, India.

[2]Assistant Professor, Department of Pharmacy, Faculty of Pharmaceutical Science, Mewar University, Gangrar, Chittorgarh-312901, Rajasthan, India.

Article Received: 06 March 2026, Article Revised: 26 March 2026, Published on: 16 April 2026

***Corresponding Author: Nisar Ahmad Waza**

Research Scholar, Department of Pharmacy, Faculty of Pharmaceutical Science, Mewar University, Gangrar, Chittorgarh-312901, Rajasthan, India.

DOI: https://doi-doi.org/101555/ijarp.7515

1. ABSTRACT

By 2026, the cancer gene therapy market, estimated at around US$ 2.8 billion, highlights a major transition from symptom-focused care to precise, potentially curative molecular strategies. Earlier methods largely relied on viral-mediated gene addition—using vectors such as adenoviruses or lent viruses to deliver functional genes. However, these approaches are now being overtaken by next-generation genome editing tools. Techniques like Base Editing and Prime Editing have introduced a new level of precision, allowing direct correction of genetic mutations without creating double-stranded DNA breaks, thereby enhancing both safety and effectiveness.

At the same time, delivery technologies have advanced considerably. Lipid Nanoparticles (LNPs) have gained prominence as a non-viral alternative due to their lower immunogenicity, scalability, and success in delivering nucleic acids in clinical settings. In parallel, the application of artificial intelligence to engineer synthetic viral capsids has improved targeting accuracy and gene transfer efficiency, overcoming many traditional delivery barriers.

The years 2025–2026 have marked important clinical achievements, including the approval of innovative therapies such as Zongertinib and Sevabertinib. These developments reflect growing regulatory trust in precision oncology and gene-based treatment modalities.

As these therapies become more complex, pharmacists are taking on expanded responsibilities in managing Advanced Therapy Medicinal Products (ATMPs). Their roles now include ensuring proper storage, safe handling, patient education, and ongoing safety monitoring. This evolving, collaborative healthcare approach is crucial for effectively integrating advanced gene therapies into standard clinical practice.

KEYWORDS: *Oncology, Gene Therapy, CRISPR-Cas9, CAR-T Cells, Viral Vectors, mRNA Nanoparticles, 2026 Clinical Trials, Pharmacists' Role.*

2. INTRODUCTION

The clinical framework of oncology is currently experiencing its most profound transformation since the introduction of cytotoxic chemotherapy. Conventional treatment strategies frequently struggle to overcome the intrinsic intratumoral heterogeneity and the pervasive challenge of multidrug resistance (MDR), often driven by the overexpression of efflux pumps like P-glycoprotein. In response, gene therapy has emerged as a transformative molecular solution, utilizing siRNA-mediated silencing to disrupt oncogenic pathways and restore drug sensitivity.

What began as foundational research in the 1990s has matured into the "one-and-done" curative philosophy of 2026. This evolution marks a transition from treating rare, monogenic conditions to confronting the world's most aggressive solid malignancies. Modern advancements in single-cell sequencing now allow for the design of personalized genetic constructs that target specific sub-clonal mutations, effectively addressing the "moving target" nature of advanced-stage cancer.

3. THE GENETIC ARCHITECTURE OF CANCER

The success of gene therapy depends on understanding the dualistic nature of the cancer genome:

- Oncogenes: Gain-of-function mutations (e.g., *KRAS, MYC*) that drive uncontrolled proliferation.
- Tumor Suppressor Genes (TSGs): Loss-of-function mutations in genes like p53 ("The Guardian of the Genome") and Rb. Gene therapy aims to restore these "brakes" on the cell cycle.

4. DELIVERY SYSTEMS: THE PHARMACOLOGICAL CORE

The clinical efficacy of any genetic intervention is fundamentally limited by its delivery vehicle. In the 2026 landscape, the "vector" is no longer viewed as a passive carrier but as a precision-engineered pharmaceutical agent.

4.1. Viral Vectors: AI-Enhanced Tropism

Viral platforms remain the cornerstone for *ex-vivo* therapies.

- Lentiviral Sophistication: Beyond simple gene addition, 2026 lentiviral designs incorporate self-inactivating (SIN) regions and tumor-specific promoters to ensure that transgene expression is restricted solely to malignant cells, significantly reducing off-target toxicities.
- AAV and Synthetic Capsids: Adeno-associated viruses (AAV) have been revolutionized by Machine Learning. By utilizing AI-driven "capsid shuffling," scientists have developed vectors that bypass the liver—the traditional site of sequestration—and prioritize delivery to muscle or lung tissue, which is vital for treating metastatic NSCLC.

4.2. Non-Viral Vectors: The LNP Revolution

The maturation of Lipid Nanoparticles (LNPs) has bridged the gap between vaccine technology and cancer therapeutics.

- Ionizable Lipid Chemistry: Modern LNPs utilize pH-sensitive lipids that facilitate endosomal escape, ensuring the genetic payload (e.g., mRNA or CRISPR components) is released directly into the cytoplasm.
- Targeted Ligands: 2026 research has introduced GalNAc-conjugated LNPs and antibody-fragment-coated shells that actively seek out tumor-associated antigens (TAAs), providing a "homing" mechanism previously exclusive to viral vectors.

5. REVOLUTIONARY STRATEGIES: CAR-T 2.0 AND CRISPR

5.1. Allogeneic "Off-the-Shelf" CAR-T

Historically, CAR-T required a bespoke process using the patient’s own cells (Autologous). By 2026, the focus has shifted to Allogeneic products. Using CRISPR to "knock out" the T-cell receptor (TCR), scientists can create universal donor cells that are ready for immediate use, reducing costs and wait times.

5.2. CRISPR, Base, and Prime Editing

While early CRISPR-Cas9 was famous for cutting DNA, Base Editing (new in 2025/26) is safer. It allows for single-letter changes (A to G, C to T) without breaking the DNA backbone, which significantly reduces the risk of accidental new cancers (genotoxicity).

6. 2025–2026 CLINICAL & REGULATORY MILESTONES

The current year marks a historic high in regulatory approvals for genetic oncology. A key highlight is the February 26, 2026, FDA accelerated approval of Hernexeos (zongertinib).

- Mechanism of Action: Hernexeos is an irreversible tyrosine kinase inhibitor (TKI) specifically designed for adults with advanced HER2 (ERBB2)-mutant non-small cell lung cancer.
- Clinical Impact: Data from the Beamion LUNG-1 trial demonstrated an unprecedented 76% objective response rate (ORR) in treatment-naïve patients. This follows the late-2025 approval of Hyrnuo (sevabertinib), solidifying HER2-targeting as the new standard for precision lung cancer care.

The following table summarizes the breakthrough approvals that have defined the field in the last 18 months:

Agent Name	Approval Date	Indication	Mechanism
Zongertinib	Feb 2026	HER2+ NSCLC	Targeted TKD Inhibitor
Sevabertinib	Nov 2025	Metastatic Lung Cancer	ERBB2 Activating Target
Afami-cel	2024	Synovial Sarcoma	MAGE-A4 directed TCR
Ziftomenib	Nov 2025	Refractory AML	NPM1 Mutation Inhibitor

7. THE PHARMACIST'S ROLE IN 2026

As gene therapies like Hernexeos and various CAR-T products enter routine clinical use, the role of the hospital pharmacist has evolved into Genomic Stewardship. This involves a rigorous set of Standard Operating Procedures (SOPs):

- Cryogenic & Cold-Chain Logistics: Pharmacists now manage specialized vapor-phase nitrogen dewars to maintain product integrity at -150°C.
- Biosafety & GMO Governance: Because many gene therapies are classified as Genetically Modified Organisms (GMOs), the pharmacy is responsible for ensuring "deliberate release" protocols are followed, including the use of Class II biosafety cabinets for aseptic preparation.

- Toxicovigilance: The pharmacist plays a lead role in the multidisciplinary team monitoring for Cytokine Release Syndrome (CRS) and ICANS, managing the immediate supply of tocilizumab and high-dose corticosteroids.

Pharmacists are now essential members of the gene therapy team. Key responsibilities include:

1. Cryogenic Management: Maintaining the cold chain at -150°C.
2. Safety Monitoring: Managing Cytokine Release Syndrome (CRS).
3. Compounding: Operating in Class II/III biosafety cabinets to prepare genetic constructs.

8. CHALLENGES AND ETHICAL CONSIDERATIONS

Notwithstanding the current clinical momentum, several formidable obstacles continue to impede the universal adoption of genetic oncology. Chief among these is the economic burden; with individual dose costs escalating to between US$ 2 million and US$ 4 million, a profound crisis in global health equity has emerged, threatening to limit these cures to high-income nations. Furthermore, manufacturing inefficiencies—specifically the protracted "vein-to-vein" latency period required for autologous cell processing—remain a primary logistical bottleneck. Finally, the field must navigate a complex ethical landscape, as the regulatory demarcation between non-heritable somatic intervention and controversial germline modification remains a subject of intense international debate.

9. CONCLUSION

The year 2026 represents a historic inflection point—the definitive commencement of the "Golden Age" of genetic oncology. This era is characterized by a fundamental shift from stochastic gene addition toward the high-fidelity precision of AI-driven vector synthesis and CRISPR-mediated genomic surgery. The integration of deep learning models has allowed for the design of synthetic capsids that successfully navigate the complex immune landscape, while advancements in Base and Prime Editing have virtually eliminated the genotoxic risks that once hindered the clinical translation of genome editing.

As the field looks toward 2030, the primary objective is the industrialization of "living drugs." To achieve this, the industry must prioritize three strategic pillars:

1. Cost Rationalization: Transitioning from bespoke, labor-intensive manufacturing to automated, high-yield platforms (such as the CARvivo™ in-vivo programming system) to make therapies economically sustainable.

2. Solid Tumor Infiltration: Leveraging oncolytic virotherapy and "armored" CAR-T cells to overcome the suppressive physical and chemical barriers of the solid tumor microenvironment.
3. Universal Access: Establishing allogeneic "off-the-shelf" banks as the standard of care, ensuring that these curative molecular interventions are no longer a "luxury" for the few, but a first-line reality for all patients worldwide.

Ultimately, the milestones of 2026—epitomized by the rapid adoption of targeted agents like Hernexeos—confirm that we are no longer merely managing cancer; we are architecting its obsolescence.

10. REFERENCES

Category 1: Introduction & Global Market (Chapter 1 & 2)

1. World Health Organization (2025). *Global Cancer Statistics: 2024–2025 Reports on Targeted Intervention.* WHO Press.
2. Fortune Business Insights (2026). *Cancer Gene Therapy Market Size, Share & COVID-19 Impact Analysis, 2026-2032.*
3. Mullard, A. (2025). *2024 FDA Drug Approvals: A Record Year for Biologics and Gene Therapies.* Nature Reviews Drug Discovery, 24(1), 3-8.
4. Pardi, N. & Weissman, D. (2024). *The Future of mRNA Technologies in Oncology: Beyond the Pandemic.* Journal of Internal Medicine.

Category 2: Delivery Systems (Viral & Non-Viral) (Chapter 4)

5. Kuzmin, D. A., et al. (2025). *The Clinical Landscape of Viral Vectors: A 2025 Update.* Nature Reviews Drug Discovery.
6. Wang, D. & Gao, G. (2024). *State-of-the-art AAV Vector Engineering for Next-Generation Gene Therapy.* Human Gene Therapy.
7. Culinary, S. R., et al. (2026). *Synthetic Lipid Nanoparticles: Optimizing the Ionizable Lipid for Solid Tumor Penetration.* International Journal of Pharmaceutics.
8. Liu, C. & Zhang, L. (2025). *Exosomes as Bio-inspired Vehicles for Cancer Gene Delivery: Overcoming the Blood-Brain Barrier.* Journal of Controlled Release.
9. Mitchell, M. J., et al. (2024). *Engineering Precision Nanoparticles for Drug Delivery.* Nature Reviews Drug Discovery.

Category 3: CRISPR, Base & Prime Editing (Chapter 5)

10. Anzalone, A. V., et al. (2025). *Prime Editing: Progress and Clinical Perspectives in Genomic Medicine.* Cell.

11. Gaudelli, N. M. & Liu, D. R. (2024). *Base Editing: Precision Chemistry at the Single-Nucleotide Level.* Annual Review of Biochemistry.
12. Doudna, J. A. (2025). *The CRISPR Revolution in 2025: From Rare Diseases to Common Cancers.* Science.
13. Innovative Genomics Institute (2026). *Clinical Trial Database: CRISPR-Cas9 Applications in Oncology.* [Online Database].

Category 4: CAR-T and Immunotherapy (Chapter 5)

14. June, C. H. & Sadelain, M. (2024). *Chimeric Antigen Receptor Therapy: The Next Decade.* New England Journal of Medicine.
15. Labanieh, L. & Mackall, C. L. (2025). *Next-Generation CAR-T Cells: Overcoming the Solid Tumor Microenvironment.* Nature Biomedical Engineering.
16. Depil, S., et al. (2024). *Off-the-shelf Chimeric Antigen Receptor T Cells: How Close Are We?* Nature Reviews Drug Discovery.
17. NexCAR19 Trial Group (2025). *Low-cost CAR-T Cell Therapy in Emerging Markets: Results from a Phase II Clinical Trial in India.* The Lancet Oncology.

Category 5: Clinical Trials & FDA Reports (Chapter 6)

18. U.S. Food and Drug Administration (2026). *CBER Approved Cellular and Gene Therapy Products: 2026 Comprehensive List.*
19. ClinicalTrials.gov (2026). *Active Phase III Trials in Oncolytic Virotherapy and mRNA Cancer Vaccines.* National Institutes of Health.
20. European Medicines Agency (2025). *EMA Guidelines on Quality, Safety, and Efficacy of ATMPs.*
21. Johnson, D. et al. (2026). *Impact of Zongertinib on HER2-Positive NSCLC: A Multicenter Phase III Analysis.* Journal of Clinical Oncology.

Category 6: Pharmacy Practice & Ethics (Chapter 7)

22. American Society of Health-System Pharmacists (2025). *ASHP Guidelines on the Pharmacist's Role in Managing Gene and Cell Therapies.*
23. Schuh, M. J. (2024). *The Pharmacist's Guide to Advanced Therapy Medicinal Products (ATMPs).* American Journal of Pharmaceutical Education.
24. Kimmelman, J. (2025). *Ethical Challenges in Gene Therapy: Costs, Access, and Germline Boundaries.* Hastings Center Report.
25. Eckstein, L. & Joffe, S. (2026). *Value-Based Pricing for One-Time Gene Curations: A 2026 Economic Model.* Value in Health